AOD9604
$45.00
AOD 9604, also known as Advanced Obesity Drug 9604, is a synthetic peptide fragment derived from the C-terminus of human growth hormone (HGH).
Unlike HGH, which has a broad spectrum of effects on growth and metabolism, AOD 9604 specifically targets fat metabolism by mimicking the fat-burning effects of HGH without influencing blood sugar levels or promoting muscle growth.
This makes it a promising candidate for those looking to manage weight and improve overall metabolic health.
| Quantity |
(6mg x 10 Vials) |
|---|
What Are the Benefits of AOD 9604?
AOD 9604 offers a range of benefits that make it an appealing option for individuals seeking to optimize their health and well-being. Here are some of the key advantages:
1. Fat Loss
AOD 9604 is primarily known for its ability to promote fat loss. It stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of new fat), helping individuals achieve a leaner physique
2. Improved Metabolic Health
By enhancing fat metabolism, AOD 9604 can improve overall metabolic health. This includes better regulation of blood sugar levels and a reduced risk of metabolic disorders such as type 2 diabetes.
3. Joint and Cartilage Repair
Research suggests that AOD 9604 may aid in the repair and regeneration of joint cartilage, making it beneficial for those suffering from joint pain or osteoarthritis.
4. No Negative Impact on Blood Sugar Levels
Unlike other weight loss treatments, AOD 9604 does not negatively affect blood sugar levels, making it a safer option for individuals with diabetes or insulin resistance.
5. Enhanced Recovery and Healing
AOD 9604 has been found to accelerate the healing process of wounds and injuries, making it a valuable tool for athletes and individuals recovering from surgery.
Related products
Humanin | Humanin peptide
$80.00
IGF-1 DES
$65.00
Lipopeptide (Topical)
$65.00 – $165.00Price range: $65.00 through $165.00
LL-37 (CAP-18)
$65.00
Matrixyl (Topical)
$145.00
Mod GRF, GHRP-6 (Blend)
$65.00

Reviews
There are no reviews yet.